Loading
Life sciences · Journal article
Frontiers in Medicine · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Serplulimab is the first anti-PD-1 monoclonal antibody to receive marketing approval for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) worldwide. To date, only sporadic cases of immune-induced adverse events (irAEs) secondary to serplulimab have been reported. Herein, we report a case of a man who suffered from a toxic epidermal necrolysis-like reaction after treatment with serplulimab and was successfully treated with comprehensive therapy. Additionally, we review the literature on toxic epidermal necrolysis (TEN) associated with serplulimab and provide a detailed description of the clinical symptoms, underlying mechanisms, and treatment for a more comprehensive understanding of immune-related TEN for the first time. Case summary A 76-year-old man diagnosed with ES-SCLC developed sporadic red maculopapular eruptions 7 days after the first cycle of serplulimab infusion, which rapidly progressed to blisters and ulceration, ultimately deteriorating to extensive epidermal detachment within a short time. A diagnosis of a TEN-like reaction was conservatively made due to the lack of a skin biopsy. The patient was successfully treated with a multifaceted management approach consisting of immune suppression using a combination of corticosteroids and intravenous immunoglobulin (IVIG), anti-infection treatment based on susceptibility testing, personalized wound care, and nutritional support. Conclusion Despite serplulimab having reshaped the treatment landscape of ES-SCLC, the occurrence of rare but potentially fatal TEN secondary to serplulimab should not be ignored. This case illustrates that serplulimab can induce a rare but potentially fatal TEN-like reaction within a short time and underscores the importance of vigilant monitoring of skin and mucous membranes and early recognition during treatment. In addition, we highlight that a multidimensional treatment approach consisting of immune suppression, anti-infection treatment, wound care, and nutritional support is pivotal for recovery.